Syngene International Limited has informed the Exchange regarding 'Update on inspection by United States Food & Drug Administration (USFDA)'.
SYNGENE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The US Food and Drug Administration (USFDA) completed a Good Clinical Practices (GCP) compliance inspection of Syngene International's facility at Semicon Park, Bengaluru, from June 9 to June 13, 2025. The inspection concluded successfully with zero observations and no Form 483 was issued. USFDA classified the outcome as 'No Action Indicated' (NAI), the most favourable result, meaning the facility fully meets regulatory requirements. The company reaffirmed its commitment to high operating and compliance standards across all operations.
Positive for shareholders — a clean USFDA inspection with NAI classification removes regulatory overhang and reinforces confidence in Syngene's clinical research operations, likely supportive of the stock in the near term.